# Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

> **NCT00249002** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 9 (actual)

## Conditions studied

- Hemodialysis Graft Dysfunction

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT00249002
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11-01
- **Primary completion:** 2007-11-01
- **Final completion:** 2007-11-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated due to pipeline prioritization
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249002, "Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00249002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*